Aptose Biosciences Inc’s recent filing unveils that its Chair, President & CEO Rice William G. acquired Company’s shares for reported $20000.0 on Nov 25 ’24. In the deal valued at $0.20 per share,100,000 shares were bought. As a result of this transaction, Rice William G. now holds 613,252 shares worth roughly $98120.32.
Cantor Fitzgerald initiated its Aptose Biosciences Inc [APTO] rating to an Overweight in a research note published on October 19, 2020; the price target was $10. A number of analysts have revised their coverage, including Alliance Global Partners’s analysts, who began to cover the stock in late September with a ‘”a Buy”‘ rating. Maxim Group began covering APTO with “Buy” recommendation on February 20, 2020. H.C. Wainwright maintained its rating on February 06, 2020. It rated APTO as “a Buy”.
Price Performance Review of APTO
On Friday, Aptose Biosciences Inc [NASDAQ:APTO] saw its stock fall -14.68% to $0.16. Over the last five days, the stock has lost -22.33%. Aptose Biosciences Inc shares have fallen nearly -28.05% since the year began. Nevertheless, the stocks have fallen -91.69% over the past one year. While a 52-week high of $1.98 was reached on 02/12/25, a 52-week low of $0.13 was recorded on 02/19/25. SMA at 50 days reached $0.2031, while 200 days put it at $0.4854.
Levels Of Support And Resistance For APTO Stock
The 24-hour chart illustrates a support level at 0.1497, which if violated will result in even more drops to 0.1374. On the upside, there is a resistance level at 0.1772. A further resistance level may holdings at 0.1924. The Relative Strength Index (RSI) on the 14-day chart is 43.10, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0170, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 77.78%. Stochastics %K at 26.44% indicates the stock is a holding.
The most recent change occurred on January 09, 2020 when Piper Sandler began covering the stock and recommended ‘”an Overweight”‘ rating along with a $10 price target.
